Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07055087 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Prevent Cognitive Decline in GBA-associated Parkinson's Disease

Study acronym: PreCoDe
StatusNot Yet Recruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
This is a proof-of-concept trial to investigate the efficacy of prasinezumab to slow or prevent cognitive decline in people with Parkinson's disease carrying a severe mutation in the GBA (glucocerebrosidase) gene. The duration of the intervention per patient will be 104 weeks with monthly infusions. The investigators plan to enroll 120 participants (60 participants per treatment arm). This study will be conducted across Europe in the following countries: France, Germany, Italy, Luxembourg, Spain, Sweden, UK.
Trial Details
NCT Number NCT07055087
Lead Sponsor University Hospital Tuebingen
Conditions
(from sponsor)		 Parkinson's Disease
Related terms Parkinson Disease
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov